177 related articles for article (PubMed ID: 7833279)
21. Treatment of myelodysplastic syndromes with recombinant human erythropoietin.
Hellström E; Birgegård G; Lockner D; Helmers C; Ost A; Wide L
Eur J Haematol; 1991 Nov; 47(5):355-60. PubMed ID: 1761122
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes.
Musto P; Falcone A; Sanpaolo G; Bodenizza C; La Sala A; Perla G; Carella AM
Br J Haematol; 2003 Jul; 122(2):269-71. PubMed ID: 12846896
[TBL] [Abstract][Full Text] [Related]
23. Erythropoietin as an independent prognostic factor in myelodysplastic syndromes.
Boyko O; Simonova M; Knysh N; Danysh O; Vygovska Y; Masliak Z
Exp Oncol; 2021 Mar; 43(1):41-45. PubMed ID: 33785713
[TBL] [Abstract][Full Text] [Related]
24. Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels.
Santini V; Almeida A; Giagounidis A; Skikne B; Beach CL; Weaver J; Tu N; Fenaux P
Leuk Lymphoma; 2020 Jun; 61(6):1475-1483. PubMed ID: 32064987
[TBL] [Abstract][Full Text] [Related]
25. A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes.
Hellström-Lindberg E; Birgegård G; Carlsson M; Carneskog J; Dahl IM; Dybedal I; Grimfors G; Merk K; Tangen JM; Winqvist I
Leuk Lymphoma; 1993 Oct; 11(3-4):221-8. PubMed ID: 7505147
[TBL] [Abstract][Full Text] [Related]
26. Distribution of serum erythropoietin levels in Japanese patients with myelodysplastic syndromes.
Suzuki T; Oh I; Ohmine K; Meguro A; Mori M; Fujiwara S; Yamamoto C; Nagai T; Ozawa K
Int J Hematol; 2015 Jan; 101(1):32-6. PubMed ID: 25374009
[TBL] [Abstract][Full Text] [Related]
27. Long-term follow-up of 18 patients with myelodysplastic syndromes responding to recombinant erythropoietin treatment.
Hast R; Wallvik J; Folin A; Bernell P; Stenke L
Leuk Res; 2001 Jan; 25(1):13-18. PubMed ID: 11137555
[TBL] [Abstract][Full Text] [Related]
28. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS).
Rose EH; Abels RI; Nelson RA; McCullough DM; Lessin L
Br J Haematol; 1995 Apr; 89(4):831-7. PubMed ID: 7772519
[TBL] [Abstract][Full Text] [Related]
29. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment.
Verhoef GE; Zachée P; Ferrant A; Demuynck H; Selleslag D; Van Hove L; Deckers F; Boogaerts MA
Ann Hematol; 1992 Jan; 64(1):16-21. PubMed ID: 1739754
[TBL] [Abstract][Full Text] [Related]
30. Measurement of serum cytokine levels in patients with myelodysplastic syndromes.
Verhoef GE; De Schouwer P; Ceuppens JL; Van Damme J; Goossens W; Boogaerts MA
Leukemia; 1992 Dec; 6(12):1268-72. PubMed ID: 1280751
[TBL] [Abstract][Full Text] [Related]
31. Recombinant human erythropoietin for treatment of myelodysplastic syndromes.
Rafanelli D; Grossi A; Longo G; Vannucchi AM; Bacci P; Ferrini PR
Leukemia; 1992 Apr; 6(4):323-7. PubMed ID: 1588794
[TBL] [Abstract][Full Text] [Related]
32. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes.
Stein RS; Abels RI; Krantz SB
Blood; 1991 Oct; 78(7):1658-63. PubMed ID: 1912554
[TBL] [Abstract][Full Text] [Related]
33. Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes.
Balleari E; Clavio M; Arboscello E; Bellodi A; Bruzzone A; Del Corso L; Lucchetti MV; Miglino M; Passalia C; Pierri I; Ponassi I; Oneto C; Racchi O; Scudeletti M; Vignolo L; Zoppoli G; Gobbi M; Ghio R
Leuk Res; 2011 Nov; 35(11):1472-6. PubMed ID: 21794914
[TBL] [Abstract][Full Text] [Related]
34. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis.
Moyo V; Lefebvre P; Duh MS; Yektashenas B; Mundle S
Ann Hematol; 2008 Jul; 87(7):527-36. PubMed ID: 18351340
[TBL] [Abstract][Full Text] [Related]
35. Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes.
Hattakitpanitchakul S; Kobbuaklee S; Wudhikarn K; Polprasert C
Asian Pac J Cancer Prev; 2021 Dec; 22(12):4037-4042. PubMed ID: 34967586
[TBL] [Abstract][Full Text] [Related]
36. Serum erythropoietin level and marrow erythroid infiltration predict response to recombinant human erythropoietin in myelodysplastic syndromes.
Depaoli L; Levis A; Isabella N; Ficara F; Priotto C; Lista P; Foà R; Resegotti L
Haematologica; 1993; 78(2):118-22. PubMed ID: 8349187
[TBL] [Abstract][Full Text] [Related]
37. In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels.
Zwierzina H; Bammer T; Rollinger-Holzinger I; Herold M; Fenaux P; Nüssler V; Hoflehner E; Geissler D
Clin Cancer Res; 1996 Jun; 2(6):1031-8. PubMed ID: 9816264
[TBL] [Abstract][Full Text] [Related]
38. Circadian rhythm of serum erythropoietin in myelodysplastic syndromes.
Pasqualetti P; Collacciani A; Casale R
Eur Rev Med Pharmacol Sci; 2000; 4(5-6):111-5. PubMed ID: 11710507
[TBL] [Abstract][Full Text] [Related]
39. Distribution of serum erythropoietin levels in lower risk myelodysplastic syndrome cases with anemia.
Nakazaki K; Nannya Y; Kurokawa M
Int J Hematol; 2014 Jan; 99(1):53-6. PubMed ID: 24307517
[TBL] [Abstract][Full Text] [Related]
40. Iron Support in Erythropoietin Treatment in Myelodysplastic Syndrome Patients Affected by Low-Risk Refractory Anaemia: Real-Life Evidence from an Italian Setting.
Giordano G; Cutuli MA; Lucchesi A; Magnifico I; Venditti N; Vergalito F; Gasperi M; Di Marco R
Acta Haematol; 2020; 143(2):155-162. PubMed ID: 31533096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
